YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials
4 indexed studies · 3 currently recruiting
- RecruitingTherapeutic confirmatory (Phase III)
IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
This study looks at a new way to treat advanced lung cancer. It compares continuing a combination of two immunotherapy drugs (Nivolumab and Ipilimumab) after initial treatment with simply watching to see what happens. The goal is to find out which approach works better at keeping the cancer from growing.
For: Non small cell lung cancerFrance - AuthorisedTherapeutic exploratory (Phase II)
Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
This study looks at two types of drug combinations (nivolumab and ipilimumab) for people with advanced bowel cancer that has specific genetic changes (dMMR and/or MSI). It's a Phase II study checking how safe these treatments are and how well they stop the cancer from growing.
For: Patients with DMMR and/or MSI metastatic colorectal cancerFrance - RecruitingTherapeutic exploratory (Phase II)
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
This study is testing two new medicines, YERVOY and OPDIVO, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see how well they control the cancer and if they cause any side effects.
For: castration-resistant prostate cancerNetherlands - RecruitingTherapeutic exploratory (Phase II)
Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases_NIVIPI-Brain
This clinical trial is testing a combination of two immunotherapy medicines and a short course of chemotherapy for people newly diagnosed with advanced non-small cell lung cancer that has spread to the brain. Researchers want to see if this treatment can safely control cancer growth in the brain for at least six months.
For: Non-small cell lung cancer with brain metastasisSpain